DGAP-News

APONTIS PHARMA AG: Notification on the implementation of stabilization measures

DGAP-News: APONTIS PHARMA AG / Key word(s): Miscellaneous APONTIS PHARMA AG: Notification on the implementation of stabilization measures 28.05.2021 / 20:05 The issuer is solely responsible for the content of this announcement. NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THE PRESS RELEASE.

28 May 2021

APONTIS PHARMA AG

Disclosure in accordance with Article 5 para. 4 lit. (b) and para. 5 of Regulation (EU) No 596/2014 of the European Parliament and of the Council on market abuse ("Market Abuse Regulation") of 16 April 2014 and in accordance with Article 6 para. 2 of the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 on the implementation of stabilisation measures

Following the pre-stabilisation announcement dated 29 April 2021, the stabilisation manager mentioned below has informed APONTIS PHARMA AG, Monheim am Rhein, Germany, (contact person: Sven Pauly; Telefon: [phone]) that stabilisations (within the meaning of Article 3 para. 2 lit. (d) of the Market Abuse Regulation) have taken place with respect to the offer of the following securities as indicated below:

The Securities:

Issuer:	APONTIS PHARMA AG
Guarantor (if applicable):	n/a
Aggregate nominal amount of the offer (excluding over-allotment option):	4,600,000
Description:	Ordinary shares with no par value ISIN DE000A3CMGM5
Offer price:	EUR 19.00

 

Stabilisation: